Evaluation of In Vitro Cross-Reactivity to Avian H5N1 and Pandemic H1N1 2009 Influenza Following Prime Boost Regimens of Seasonal Influenza Vaccination in Healthy Human Subjects: A Randomised Trial

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Bethell, Delia ^a   Saunders, David ^a   Jongkaewwattana, Anan ^b   Kramyu, Jarin ^b   Thitithayanont, Arunee ^c   Wiboon ut, Suwimon ^c   Yongvanitchit, Kosol ^a   Limsalakpetch, Amporn ^a   Kum Arb, Utaiwan ^a   Uthaimongkol, Nichapat ^a   Garcia, Jean Michel ^d   Timmermans, Ans E ^a   Peiris, Malik ^d   Thomas, Stephen ^a   Engering, Anneke ^a   Jarman, Richard G ^a   Mongkolsirichaikul, Duangrat ^a   Mason, Carl ^a   Khemnu, Nuanpan ^a   Tyner, Stuart D ^a   Fukuda, Mark M ^a   Walsh, Douglas S ^a   Pichyangkul, Sathit ^a   more..

^a ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^b NATIONAL SCIENCE AND TECHNOLOGY DEVELOPMENT AGENCY   (Thailand)

^c Mahidol University ^*  (Thailand)

^d HKU PASTEUR RESEARCH CENTRE   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INFLUENZA VACCINE; INTERLEUKIN 2;

2009 H1N1 INFLUENZA; ABDOMINAL PAIN; ADULT; ANOREXIA; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CD4 LYMPHOCYTE PERCENTAGE; CD4+ T LYMPHOCYTE; CHILL; CONTROLLED STUDY; COUGHING; CROSS PROTECTION; CROSS REACTION; CYTOKINE RESPONSE; DIZZINESS; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEASIBILITY STUDY; FEMALE; GASTROINTESTINAL SYMPTOM; HEMAGGLUTINATION INHIBITION; HUMAN; HUMAN EXPERIMENT; HUMORAL IMMUNITY; IN VITRO STUDY; INFLUENZA A (H5N1); INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H5N1; INJECTION SITE BRUISE; INJECTION SITE IMPAIRED MOVEMENT; INJECTION SITE REACTION; INJECTION SITE SWELLING; MALE; MYALGIA; NAUSEA; NONHUMAN; NORMAL HUMAN; NOSE OBSTRUCTION; OPEN STUDY; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; SEASONAL INFLUENZA; SINGLE DRUG DOSE; SORE THROAT; VIRUS NEUTRALIZATION; VOMITING;

ADOLESCENT; ADULT; ANIMALS; ANTIBODIES, VIRAL; BIRDS; CROSS REACTIONS; FEASIBILITY STUDIES; FEMALE; HEALTH; HUMANS; IMMUNIZATION, SECONDARY; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA IN BIRDS; INFLUENZA, HUMAN; MALE; MIDDLE AGED; ORTHOMYXOVIRIDAE; PANDEMICS; PILOT PROJECTS; SAFETY; SEASONS; T-LYMPHOCYTES; VACCINATION; VIRAL VACCINES; YOUNG ADULT;

AVES; ORTHOMYXOVIRIDAE;

EID: 84875448994     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0059674     Document Type: Article

References (35)

1. World Health Organization (2013) Cumulative number of confirmed human cases of avian influenza a(H5N1) reported to WHO. Geneva.Accessed 25 February 2013. http://www.who.int/influenza/human_animal_interface/H5N1_cumulative_table_archives/en/index.html.
2. Cox RJ, Brokstad K, Ogra P, (2004) Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand J Immunol 59: 1-15.
3. Carter NJ, Curran MP, (2011) Live attenuated influenza vaccine (FluMist(R); Fluenz): a review of its use in the prevention of seasonal influenza in children and adults. Drugs 71: 1591-1622.
4. Ambrose CS, Walker RE, Connor EM, (2006) Live attenuated influenza vaccine in children. Semin Pediatr Infect Dis 17: 206-212.
5. Verrier F, Burda S, Belshe R, Duliege AM, Excler JL, et al. (2000) A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates. J Virol 74: 10025-10033.
6. McConkey SJ, Reece WH, Moorthy VS, Webster D, Dunachie S, et al. (2003) Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med 9: 729-735.
7. Gomez CE, Najera JL, Domingo-Gil E, Ochoa-Callejero L, Gonzalez-Aseguinolaza G, et al. (2007) Virus distribution of the attenuated MVA and NYVAC poxvirus strains in mice. J Gen Virol 88: 2473-2478.
8. Wei CJ, Boyington JC, McTamney PM, Kong WP, Pearce MB, et al. (2010) Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science 329: 1060-1064.
9. Garcia JM, Lagarde N, Ma ES, de Jong MD, Peiris JS, (2010) Optimization and evaluation of an influenza A (H5) pseudotyped lentiviral particle-based serological assay. J Clin Virol 47: 29-33.
10. Grandea AG, Olsen OA, Cox TC, Renshaw M, Hammond PW, et al. (2010) Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses. Proc Natl Acad Sci U S A 107: 12658-12663.
11. Lambre CR, Terzidis H, Greffard A, Webster RG, (1990) Measurement of anti-influenza neuraminidase antibody using a peroxidase-linked lectin and microtitre plates coated with natural substrates. J Immunol Methods 135: 49-57.
12. Yewdell JW, Bennink JR, Smith GL, Moss B, (1985) Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes. Proc Natl Acad Sci U S A 82: 1785-1789.
13. Browne RH, (1995) On the use of a pilot sample for sample size determination. Stat Med 14: 1933-1940.
14. Lancaster GA, Dodd S, Williamson PR, (2004) Design and analysis of pilot studies: recommendations for good practice. J Eval Clin Pract 10: 307-312.
15. Stephenson I BR, Nicholson KG, Podda A, Wood JM, Zambon MC, et al. (2005) Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J Infect Dis 191: 1210-1215.
16. Lin JZJ, Dong X, Fang H, Chen J, Su N, et al. (2006) Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet 368: 991-997.
17. Nicholson KG CA, Podda A, Stephensen I, Wood J, Ypema E, et al. (2001) Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 357: 1937-1943.
18. Schulz KF, Altman DG, Moher D, (2010) CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ 340: c332.
19. Gioia C, Castilletti C, Tempestilli M, Piacentini P, Bordi L, et al. (2008) Cross-subtype immunity against avian influenza in persons recently vaccinated for influenza. Emerg Infect Dis 14: 121-128.
20. Corti D, Langedijk JP, Hinz A, Seaman MS, Vanzetta F, et al. (2010) Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One 5: e8805.
21. Wrammert J, Koutsonanos D, Li GM, Edupuganti S, Sui J, et al. (2011) Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med 208: 181-193.
22. Nakaya HI, Wrammert J, Lee EK, Racioppi L, Marie-Kunze S, et al. (2011) Systems biology of vaccination for seasonal influenza in humans. Nat Immunol 12: 786-795.
23. Onodera T, Takahashi Y, Yokoi Y, Ato M, Kodama Y, et al. (2012) Memory B cells in the lung participate in protective humoral immune responses to pulmonary influenza virus reinfection. Proc Natl Acad Sci U S A 109: 2485-2490.
24. Murphy BR, Kasel JA, Chanock RM, (1972) Association of serum anti-neuraminidase antibody with resistance to influenza in man. N Engl J Med 286: 1329-1332.
25. Monto AS, Kendal AP, (1973) Effect of neuraminidase antibody on Hong Kong influenza. Lancet 1: 623-625.
26. Neuzil KM JL, Nelson J, Klimov A, Cox N, Bridges CB, et al. (2006) Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5-8-year-old children. J Infect Dis 194: 1032-1039.
27. Greenbaum JA, Kotturi MF, Kim Y, Oseroff C, Vaughan K, et al. (2009) Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human population. Proc Natl Acad Sci U S A 106: 20365-20370.
28. Lee LY, Ha do LA, Simmons C, de Jong MD, Chau NV, et al. (2008) Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals. J Clin Invest 118: 3478-3490.
29. Ge X, Tan V, Bollyky PL, Standifer NE, James EA, et al. (2010) Assessment of seasonal influenza A virus-specific CD4 T-cell responses to 2009 pandemic H1N1 swine-origin influenza A virus. J Virol 84: 3312-3319.
30. Yap KL, Ada GL, (1978) Cytotoxic T cells in the lungs of mice infected with an influenza A virus. Scand J Immunol 7: 73-80.
31. Webster RG, Askonas BA, (1980) Cross-protection and cross-reactive cytotoxic T cells induced by influenza virus vaccines in mice. Eur J Immunol 10: 396-401.
32. Guo H, Santiago F, Lambert K, Takimoto T, Topham DJ, (2011) T cell-mediated protection against lethal 2009 pandemic H1N1 influenza virus infection in a mouse model. J Virol 85: 448-455.
33. Wilkinson TM, Li CK, Chui CS, Huang AK, Perkins M, et al. (2012) Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat Med 18: 274-280.
34. Eick AA, Wang Z, Hughes H, Ford SM, Tobler SK, (2009) Comparison of the trivalent live attenuated vs. inactivated influenza vaccines among U.S. military service members. Vaccine 27: 3568-3575.
35. Wang Z, Tobler S, Roayaei J, Eick A, (2009) Live attenuated or inactivated influenza vaccines and medical encounters for respiratory illnesses among US military personnel. JAMA 301: 945-953.